Leerink Partnrs Brokers Lift Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Leerink Partnrs upped their Q4 2025 EPS estimates for shares of Edwards Lifesciences in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings of $0.64 per share for the quarter, up from their previous estimate of $0.63. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2029 earnings at $4.19 EPS.

Several other equities analysts have also recently commented on the stock. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Truist Financial dropped their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Finally, Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $78.55.

Edwards Lifesciences Stock Performance

EW stock opened at $71.56 on Thursday. The stock has a market cap of $42.07 billion, a P/E ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a 50 day simple moving average of $71.31 and a 200 day simple moving average of $70.85. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $95.25.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock valued at $5,163,062 in the last ninety days. Company insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 5.3% during the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after buying an additional 1,678,154 shares during the period. Geode Capital Management LLC boosted its stake in Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock valued at $1,007,520,000 after buying an additional 126,194 shares in the last quarter. Fisher Asset Management LLC grew its position in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after acquiring an additional 696,965 shares during the period. Finally, Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter worth $610,895,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.